Use of plasma metabolomics to analyze phenotype-genotype relationships in young hypercholesterolemic females[S]
暂无分享,去创建一个
A. Zwinderman | G. Dallinga-Thie | A. Groen | J. Kuivenhoven | A. Rimbert | X. Zhang | W. Balder | Xiang Zhang
[1] J. Danesh,et al. Metabolomic Consequences of Genetic Inhibition of PCSK9 Compared With Statin Treatment , 2018, Circulation.
[2] J. Danesh,et al. Lipoprotein signatures of cholesteryl ester transfer protein and HMG-CoA reductase inhibition , 2018, bioRxiv.
[3] R. Sinke,et al. Genetics, Lifestyle, and Low-Density Lipoprotein Cholesterol in Young and Apparently Healthy Women , 2018, Circulation.
[4] R. Collins,et al. Lipids, Lipoproteins, and Metabolites and Risk of Myocardial Infarction and Stroke , 2018, Journal of the American College of Cardiology.
[5] A. Pereira,et al. Clinical, Anthropometric and Biochemical Characteristics of Patients with or without Genetically Confirmed Familial Hypercholesterolemia , 2018, Arquivos brasileiros de cardiologia.
[6] R. Krauss,et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease , 2018 .
[7] S. Irani,et al. microRNA-30c reduces plasma cholesterol in homozygous familial hypercholesterolemic and type 2 diabetic mouse models , 2017, Journal of Lipid Research.
[8] Vhw Dissanayake,et al. Genetic determinants of inherited susceptibility to hypercholesterolemia – a comprehensive literature review , 2017, Lipids in Health and Disease.
[9] Lale Tokgözoğlu,et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel , 2017, European heart journal.
[10] John F. Robinson,et al. Polygenic Versus Monogenic Causes of Hypercholesterolemia Ascertained Clinically , 2016, Arteriosclerosis, thrombosis, and vascular biology.
[11] E. Boerwinkle,et al. Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease. , 2016, The New England journal of medicine.
[12] A. Hofman,et al. Blood lipids influence DNA methylation in circulating cells , 2016, Genome Biology.
[13] J. Danesh,et al. Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia. , 2016, Journal of the American College of Cardiology.
[14] M. Swertz,et al. CoNVaDING: Single Exon Variation Detection in Targeted NGS Data , 2016, Human mutation.
[15] Alun D. Hughes,et al. Metabolomic Profiling of Statin Use and Genetic Inhibition of HMG-CoA Reductase , 2016, Journal of the American College of Cardiology.
[16] Barbara Plecko,et al. CCC- and WASH-mediated endosomal sorting of LDLR is required for normal clearance of circulating LDL , 2016, Nature Communications.
[17] J. Goldstein,et al. A Century of Cholesterol and Coronaries: From Plaques to Genes to Statins , 2015, Cell.
[18] Tom R. Gaunt,et al. Metabolite profiling and cardiovascular event risk: a prospective study of 3 population-based cohorts. , 2015, Circulation.
[19] Pasi Soininen,et al. Quantitative serum nuclear magnetic resonance metabolomics in cardiovascular epidemiology and genetics. , 2015, Circulation. Cardiovascular genetics.
[20] S. Humphries,et al. Whole exome sequencing of familial hypercholesterolaemia patients negative for LDLR/APOB/PCSK9 mutations , 2014, Journal of Medical Genetics.
[21] Pieter B. T. Neerincx,et al. Supplementary Information Whole-genome sequence variation , population structure and demographic history of the Dutch population , 2022 .
[22] Zhi-ping Chen,et al. A lincRNA-DYNLRB2-2/GPR119/GLP-1R/ABCA1-dependent signal transduction pathway is essential for the regulation of cholesterol homeostasis , 2014, Journal of Lipid Research.
[23] Toomas Haller,et al. Biomarker Profiling by Nuclear Magnetic Resonance Spectroscopy for the Prediction of All-Cause Mortality: An Observational Study of 17,345 Persons , 2014, PLoS medicine.
[24] Sonia Shah,et al. Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study , 2013, The Lancet.
[25] J. Bonnet,et al. Constitutive inhibition of plasma CETP by apolipoprotein C1 is blunted in dyslipidemic patients with coronary artery disease[S] , 2012, Journal of Lipid Research.
[26] Tanya M. Teslovich,et al. Biological, Clinical, and Population Relevance of 95 Loci for Blood Lipids , 2010, Nature.
[27] J. Weissenbach,et al. A fourth locus for autosomal dominant hypercholesterolemia maps at 16q22.1 , 2010, European Journal of Human Genetics.
[28] S. G. Hadfield,et al. Mutation detection rate and spectrum in familial hypercholesterolaemia patients in the UK pilot cascade project , 2010, Clinical genetics.
[29] Tom R. Gaunt,et al. Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip. , 2009, American journal of human genetics.
[30] Hadley Wickham,et al. ggplot2 - Elegant Graphics for Data Analysis (2nd Edition) , 2017 .
[31] A. Soutar,et al. Mechanisms of Disease: genetic causes of familial hypercholesterolemia , 2007, Nature Clinical Practice Cardiovascular Medicine.
[32] A. Tall,et al. Apolipoprotein CI Deficiency Markedly Augments Plasma Lipoprotein Changes Mediated by Human Cholesteryl Ester Transfer Protein (CETP) in CETP Transgenic/ApoCI-knocked Out Mice* , 2002, The Journal of Biological Chemistry.
[33] C. Packard,et al. Lipoprotein heterogeneity and apolipoprotein B metabolism. , 1997, Arteriosclerosis, thrombosis, and vascular biology.
[34] M. Brown,et al. A receptor-mediated pathway for cholesterol homeostasis. , 1986, Science.